Status:
TERMINATED
Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Orakine Ltd, Dublin, Ireland
Conditions:
Influenza Infection
Eligibility:
All Genders
75+ years
Phase:
PHASE3
Brief Summary
Influenza vaccination reduces the morbidity and mortality associated with influenza infection in at risk groups including the elderly and individuals with an impaired immune response, but is not total...
Detailed Description
The protection afforded by the commonly used influenza sub-unit vaccines is thought to be due principally to the production of antibodies to viral haemagglutinin. The haemagglutination inhibitory (HAI...
Eligibility Criteria
Inclusion
- Subjects aged 75 or more, -institutionalized-
- Subjects who were informed of the objectives of the study and who have given their written consent.
- Subjects who have received at least one prior influenza vaccination in the previous 5 years.
- Subjects who should be vaccinated against influenza during the 2005 vaccination campaign.
Exclusion
- Individuals with severe disease, including neoplasia, autoimmune disease, or type I diabetes
- concomitant treatment with glucocorticoid or immunosuppressive drugs splenectomy or tonsillectomy
- or incapacity to open the mouth
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00647465
Start Date
October 1 2005
End Date
March 1 2008
Last Update
March 31 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Broca-La Rochefoucauld, Service de Gérontologie 1
Paris, France, 75005